Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Biodexa Pharmaceuticals PLC announces a change in its American Depositary Receipts (ADR) ratio from one ADR representing 10,000 ordinary shares to one ADR representing 100,000 ordinary shares. The effective date is July 31, 2025. ADR holders will be required to surrender their existing ADRs for cancellation and exchange for new ADRs. This change aims to bring the company's ADR price into compliance with Nasdaq's $1.00 minimum bid price per share requirement.
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company, has announced a significant change in its American Depositary Receipts (ADR) ratio. Effective July 31, 2025, the ratio will change from one ADR representing 10,000 ordinary shares to one ADR representing 100,000 ordinary shares. This change is aimed at bringing the company's ADR price into compliance with Nasdaq's $1.00 minimum bid price per share requirement.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios